Recanalization devices should be restricted to clinical trials: Pro (kind of)

Stroke

Volumn 41, Issue 1, 2010, Pages 191-193

  Schellinger, Peter D ^a   Hacke, Werner ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

BLOOD CLOT LYSIS; CLINICAL EFFECTIVENESS; HUMAN; INTRACRANIAL STENOSIS; INTRACRANIAL STENT; MORTALITY; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; RECANALIZATION; SAFETY; STENOSIS; STENT; SURGICAL APPROACH; THERAPY EFFECT;

BALLOON DILATATION; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; THROMBOLYTIC THERAPY; VASCULAR PATENCY;

EID: 74049095119     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.569905     Document Type: Note

References (11)

1. The Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40:2761-2768
2. Moonis M. Intraarterial thrombolysis within the first three hours after acute ischemic stroke in selected patients. Stroke. 2009;40: 2611-2612.
3. Wasiewski WW, Johnston KC. Clinical trials, devices, unproven treatments, and clinical equipoise. Stroke. 2009;40:e441-e442.
4. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke. 2009;40: 2594-2600.
5. Coutts SB, Goyal M. When recanalization does not improve clinical outcomes. Stroke. 2009;40:2661.
6. Turan TN, Derdeyn CP, Fiorella D, Chimowitz MI. Treatment of atherosclerotic intracranial arterial stenosis. Stroke. 2009;40: 2257-2261.
7. Groschel K, Schnaudigel S, Pilgram SM, Wasser K, Kastrup A. A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke. 2009;40:e340-e347.
8. Hacke W, Zeumer H, Ferbert A, Brückmann H, DelZoppo G. Intraarterial thrombolytic therapy improves outcome in patients with acute vertebro-basilar occlusive disease. Stroke. 1988;19:1216-1222.
9. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
10. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
11. De Silva DA, Fink JN, Christensen S, Ebinger M, Bladin C, Levi CR, Parsons M, Butcher K, Barber PA, Donnan GA, Davis SM. Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke. 2009;40:2872-2874.